EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Immune checkpoint inhibitor-induced cardiotoxicity: from immune mechanisms to clinical surveillance and targeted therapies

Nathan K Chen, Kathryn D Hok, Narsi Chokshi, Anthony Shadid, Haydn E Rich, Lavanya Gunamalai, Marie-Francoise Doursout, Nirmal K Banda, Pooja Shivshankar

Frontiers in Cardiovascular Medicine · 29.07.2026 · 13

DOI: 10.3389/fcvm.2026.1872588 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 29.07.2026. Verfasst von Nathan K Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular Medicine, UTHealth-McGovern Medical School, Houston TX, United States. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 264 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape across a broad range of malignancies by restoring antitumor immunity through blockade of key inhibitory immune pathways, including programmed death receptor-1 (PD-1), programmed death ligand-1 (PD-L1), and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4). Yet the same widespread immune activation that drives their therapeutic benefit renders patients susceptible to immune-related adverse events (irAEs). Among these cardiovascular toxicities have emerged as a particularly critical concern, drawing growing attention within the evolving field of cardio-oncology. ICI-associated cardiotoxicity encompasses a broad clinical spectrum, ranging from myocarditis and pericarditis to arrhythmias, heart failure, and vascular complications. Of these, immune-mediated myocarditis is the most severe, carrying a disproportionately high mortality risk despite its relatively low incidence. Its pathophysiology is multifaceted, driven by dysregulated immune activation, myocardial inflammation, T-cell-mediated cytotoxicity, aberrant cytokine release, and molecular mimicry between tumor and cardiac antigens. Additional mechanisms—including B-cell activation, complement cascade signaling, and inflammasome pathway engagement—may further amplify myocardial injury and heighten arrhythmogenic susceptibility. In this review, we summarize current insights into the immunological mechanisms underlying ICI-induced cardiotoxicity and examined the expanding clinical spectrum of cardiovascular irAEs. We further discuss strategies for early detection, risk stratification, and clinical surveillance, encompassing biomarker monitoring and multimodal imaging. Emerging therapeutic strategies targeting implicated immune pathways are also being explored to mitigate cardiovascular complications without compromising anticancer efficacy. A deeper mechanistic understanding will be essential for advancing the prevention, diagnosis, and management of ICI-associated cardiovascular toxicity in oncology practice.

Schlagwörter

Stichwörter der Autor:innen

PD-1/PD-L1arrhythmiascardio-oncologycardiotoxicitycomplement immunityimmune checkpoint inhibitorsimmunotherapymyocarditis

Autor:innen und Institutionen

  • Institute of Molecular Medicine, UTHealth-McGovern Medical School, Houston TX, United States.
  • Department of Anesthesiology, UTHealth-McGovern Medical School, Houston TX, United States.
  • Division of Rheumatology-Department of Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.

Förderung

  • NIAID NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Chen, N. K., Hok, K. D., Chokshi, N., Shadid, A., Rich, H. E., Gunamalai, L., Doursout, M. F., Banda, N. K., & Shivshankar, P. (2026). Immune checkpoint inhibitor-induced cardiotoxicity: from immune mechanisms to clinical surveillance and targeted therapies. Frontiers in Cardiovascular Medicine, 13. https://doi.org/10.3389/fcvm.2026.1872588

Vancouver

Chen NK, Hok KD, Chokshi N, Shadid A, Rich HE, Gunamalai L, et al. Immune checkpoint inhibitor-induced cardiotoxicity: from immune mechanisms to clinical surveillance and targeted therapies. Frontiers in Cardiovascular Medicine. 2026;13. doi:10.3389/fcvm.2026.1872588

BibTeX
@article{Chen2026,
  author = {Chen, Nathan K and Hok, Kathryn D and Chokshi, Narsi and Shadid, Anthony and Rich, Haydn E and Gunamalai, Lavanya and Doursout, Marie-Francoise and Banda, Nirmal K and Shivshankar, Pooja},
  title = {Immune checkpoint inhibitor-induced cardiotoxicity: from immune mechanisms to clinical surveillance and targeted therapies},
  journal = {Frontiers in Cardiovascular Medicine},
  year = {2026},
  volume = {13},
  doi = {10.3389/fcvm.2026.1872588}
}
Kostenlos starten →